US 11,744,820 B2
Inhibitors of microbially induced amyloid
Timothy Sampson, Los Angeles, CA (US); Sarkis Mazmanian, Glendale, CA (US); and Anthony Stewart Campbell, Framingham, MA (US)
Assigned to Axial Therapeutics, Inc., Woburn, MA (US); and California Institute of Technology, Pasadena, CA (US)
Filed by Axial Therapeutics, Inc., Woburn, MA (US); and California Institute of Technology, Pasadena, CA (US)
Filed on Sep. 8, 2021, as Appl. No. 17/447,178.
Application 17/447,178 is a continuation of application No. 16/611,406, granted, now 11,147,792, previously published as PCT/US2018/032605, filed on May 14, 2018.
Claims priority of provisional application 62/506,457, filed on May 15, 2017.
Claims priority of provisional application 62/506,433, filed on May 15, 2017.
Prior Publication US 2022/0040145 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/353 (2006.01); A61P 25/28 (2006.01); A61P 25/16 (2006.01); A61K 31/05 (2006.01); A61K 31/192 (2006.01); A61K 31/216 (2006.01); A61K 31/235 (2006.01); A61K 31/465 (2006.01); A61K 31/522 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/353 (2013.01) [A61K 31/05 (2013.01); A61K 31/192 (2013.01); A61K 31/216 (2013.01); A61K 31/235 (2013.01); A61K 31/465 (2013.01); A61K 31/522 (2013.01); A61K 45/06 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, or treating a microbially induced amyloid disorder, the method comprising administering to a subject in need thereof a composition comprising a compound selected from the group consisting of: epigallocatechin gallate, quercetin, morin, rosmarinic acid, gallic acid, lauryl gallate, methoxyhydroquinone, curcumin, resveratrol, apigenin, nordihydroguaiaretic acid, phloretin and genistein; or pharmaceutically acceptable salts thereof.